



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
---------------	-------------	----------------------	---------------------

08/259,321 06/10/94 REZAEI

18M2/0407

PATREA L. PABST
KILPATRICK & CODY
1100 PEACHTREE STREET
STE. 2800
ATLANTA, GA 30309-4530

A CMRE 1066 CP
EXAMINER

HUTZELL, P.
ART UNIT PAPER NUMBER

6

1806
DATE MAILED:

04/07/95

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

This application has been examined Responsive to communication filed on _____ This action is made final.

A shortened statutory period for response to this action is set to expire 0 month(s), 30 days from the date of this letter.
Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

1. Notice of References Cited by Examiner, PTO-892.
2. Notice of Draftsman's Patent Drawing Review, PTO-948.
3. Notice of Art Cited by Applicant, PTO-1449.
4. Notice of Informal Patent Application, PTO-152.
5. Information on How to Effect Drawing Changes, PTO-1474.
6. _____

Part II SUMMARY OF ACTION

1. Claims 1-19 are pending in the application.

Of the above, claims _____ are withdrawn from consideration.

2. Claims _____ have been cancelled.

3. Claims _____ are allowed.

4. Claims _____ are rejected.

5. Claims _____ are objected to.

6. Claims 1-19 are subject to restriction or election requirement.

7. This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes.

8. Formal drawings are required in response to this Office action.

9. The corrected or substitute drawings have been received on _____. Under 37 C.F.R. 1.84 these drawings are acceptable; not acceptable (see explanation or Notice of Draftsman's Patent Drawing Review, PTO-948).

10. The proposed additional or substitute sheet(s) of drawings, filed on _____, has (have) been approved by the examiner; disapproved by the examiner (see explanation).

11. The proposed drawing correction, filed _____, has been approved; disapproved (see explanation).

12. Acknowledgement is made of the claim for priority under 35 U.S.C. 119. The certified copy has been received not been received been filed in parent application, serial no. _____; filed on _____.

13. Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.

14. Other

EXAMINER'S ACTION

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

I. Claims 1-5, 7-8 and 14-19, drawn to antibodies and methods of making recombinant antibodies, classified for example, in Classes 530 and 435, subclasses 387.3 and 70.21.

II. Claim 6, drawn to an antibody and a cytokine or inducer of cytokine expression, classified for example, in Class 530 subclass 351.

III. Claims 9-13, drawn to methods of treatment, classified in Class 424, subclass 133.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions (I and II) and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case the products as claimed can be used in materially different methods of use, for example, in immunoassays or in immunoaffinity purification methods.

The methods of Groups I and III differ in the method objectives, method steps and parameters and in the reagents used. The claims of Group I are drawn to methods for producing recombinant antibodies. The claims of Group III are drawn to

methods of treatment. These methods are clearly distinct.

The claims of Groups I and II are drawn to structurally and functionally distinct products which are made by different methods and have separate and distinct utilities and are deemed to be patentably distinct. Group I contains claims drawn to recombinant antibodies. Group II contains a claim drawn to an antibody together with a cytokine or an inducer of cytokine expression. The examination of these inventions requires separate and divergent searches in the U.S. patent office and in the scientific literature and requires the consideration of separate issues in determining patentability.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classifications and recognized divergent subject matter and because the searches required for the groups are not co-extensive, restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Paula Hutzell, Ph.D, whose telephone number is (703) 308-4310. The Examiner can normally be reached on Monday-Thursday from 9:00 AM-6:00 PM. The Examiner can also be reached on alternate Fridays.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, David Lacey, can be reached on (703)-308-3535. The fax phone number for this Group is (703)-305-3014.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.



PAULA K. HUTZELL
PRIMARY EXAMINER
GROUP 1800